沙美特罗替卡松粉吸入剂在支气管哮喘患者中的应用及对肺功能的影响研究

Application of salmeterol in the treatment of bronchial asthma and its effect on pulmonary function

目的观察沙美特罗替卡松粉吸入剂在支气管哮喘患者中的治疗效果及对肺功能的影响。方法取本院2013年1月至2016年1月收治支气管哮喘患者100例,随机分为对照组(n=50)和试验组(n=50)。对照组采用丙酸倍氯米松气雾剂吸入治疗,试验组采用沙美特罗替卡松粉吸入剂治疗,两组治疗前、后肺功能进行测定,采用酶联免疫吸附试验检测两组干扰素-γ及白细胞介素-4水平,比较两组临床疗效及对肺功能水平的影响。结果两组治疗前6分钟步行距离比较差异无显著性(P>0.05);试验组治疗后4周、8周及12周6分钟步行距离长于对照组(P<0.05);两组治疗前FEV1.0、1秒钟最大力气呼出的气体量(forced expiratory volume in one second,FEV1.0)/用力肺活量(forced vital capacity,FVC)、最大呼气流量(peak expiratory flow,PEF)指标比较差异无显著性(P>0.05);试验组治疗后FEV1.0/FVC、FEV1.0、PEF指标,高于对照组(P<0.05);两组治疗前干扰素-γ及IL-4水平差异无显著性(P>0.05);试验组治疗后干扰素-γ水平,高于对照组(P<0.05);试验组治疗后IL-4水平,低于对照组(P<0.05);两组治疗8周后药物不良反应发生率比较差异无显著性(P>0.05)。结论支气管哮喘患者采用沙美特罗替卡松粉吸入剂治疗效果理想,能改善患者肺功能,减少炎症反应,值得推广应用。

Objective Observe the therapeutic effect of salmeterol in the treatment of bronchial asthma and its effect on pulmonary function. Method One hundred patients with bronchial asthma were enrolled from January 2013 to January 2016.The patients were divided into control group（n=50） and observation group（n=50） by random number method. The control group was treated with beclomethasone dipropionate aerosol inhalation. In the observation group, Salmeterol was used in the treatment of Pulmicort inhalation. The lung function of the two groups before and after treatment was measured by German Yager pulmonary function instrument. The levels of interferon-γ and interleukin-4 were detected by immunosorbent assay. The effects of two groups on the pulmonary function were compared. Result There was no significant difference in the walking distance between the two groups（P〉0.05）. The walking distance of the observation group at 4, 8 and 12 weeks after treatment was longer than that of the control group（P〈0.05） FEV1.0/FVC, FEV1.0, PEF were significantly higher than those in the control group（P〈0.05）, and there was no significant difference in FEV1.0, FEV1.0/FVC, FEV1 and PEF between the two groups Interferon-γ and IL-4 levels in the observation group were significantly higher than those in the control group（P〈0.05）. The level of IL-4 in the observation group was significantly higher than that in the control group（P〈0.05）. There was no significant difference in the incidence of adverse drug reactions between the two groups after 8 weeks of treatment（P〉0.05）. Conclusion Salmeterol can be used in the treatment of bronchial asthmatic patients, which can improve the pulmonary function and reduce the inflammatory reaction. It is worthy of popularization and application.